Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
OSUR's Cash-to-Debt is ranked higher than
95% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. OSUR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OSUR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.47  Med: 21.19 Max: No Debt
Current: No Debt
Equity-to-Asset 0.89
OSUR's Equity-to-Asset is ranked higher than
93% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. OSUR: 0.89 )
Ranked among companies with meaningful Equity-to-Asset only.
OSUR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.84 Max: 0.94
Current: 0.89
0.57
0.94
Interest Coverage No Debt
OSUR's Interest Coverage is ranked higher than
93% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. OSUR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OSUR' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 9
Altman Z-Score: 21.53
Beneish M-Score: -2.44
WACC vs ROIC
11.06%
33.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 15.81
OSUR's Operating Margin % is ranked higher than
80% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. OSUR: 15.81 )
Ranked among companies with meaningful Operating Margin % only.
OSUR' s Operating Margin % Range Over the Past 10 Years
Min: -18.53  Med: -7.97 Max: 15.81
Current: 15.81
-18.53
15.81
Net Margin % 15.38
OSUR's Net Margin % is ranked higher than
85% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. OSUR: 15.38 )
Ranked among companies with meaningful Net Margin % only.
OSUR' s Net Margin % Range Over the Past 10 Years
Min: -43.98  Med: -7.4 Max: 15.38
Current: 15.38
-43.98
15.38
ROE % 11.55
OSUR's ROE % is ranked higher than
70% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. OSUR: 11.55 )
Ranked among companies with meaningful ROE % only.
OSUR' s ROE % Range Over the Past 10 Years
Min: -25.18  Med: -5.07 Max: 11.55
Current: 11.55
-25.18
11.55
ROA % 9.97
OSUR's ROA % is ranked higher than
83% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. OSUR: 9.97 )
Ranked among companies with meaningful ROA % only.
OSUR' s ROA % Range Over the Past 10 Years
Min: -20.9  Med: -4.38 Max: 9.97
Current: 9.97
-20.9
9.97
ROC (Joel Greenblatt) % 63.82
OSUR's ROC (Joel Greenblatt) % is ranked higher than
89% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. OSUR: 63.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OSUR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -47.87  Med: -22.92 Max: 63.82
Current: 63.82
-47.87
63.82
3-Year Revenue Growth Rate 8.40
OSUR's 3-Year Revenue Growth Rate is ranked higher than
66% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. OSUR: 8.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OSUR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.7  Med: 5.9 Max: 64.2
Current: 8.4
-15.7
64.2
GuruFocus has detected 3 Warning Signs with OraSure Technologies Inc $OSUR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OSUR's 10-Y Financials

Financials (Next Earnings Date: 2017-05-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

OSUR Guru Trades in Q2 2016

Paul Tudor Jones 111,236 sh (+24.31%)
Joel Greenblatt 23,074 sh (+17.91%)
Jim Simons 3,098,803 sh (+15.04%)
PRIMECAP Management 1,990,900 sh (+2.05%)
Ken Fisher 824,592 sh (unchged)
Chuck Royce 625,095 sh (-6.11%)
» More
Q3 2016

OSUR Guru Trades in Q3 2016

Joel Greenblatt 38,083 sh (+65.05%)
Jim Simons 3,971,503 sh (+28.16%)
PRIMECAP Management 2,015,900 sh (+1.26%)
Chuck Royce Sold Out
Ken Fisher 623,658 sh (-24.37%)
Paul Tudor Jones 53,291 sh (-52.09%)
» More
Q4 2016

OSUR Guru Trades in Q4 2016

Paul Tudor Jones 87,661 sh (+64.49%)
Joel Greenblatt 51,091 sh (+34.16%)
Jim Simons 4,197,303 sh (+5.69%)
PRIMECAP Management 1,262,000 sh (-37.40%)
Ken Fisher 338,964 sh (-45.65%)
» More
Q1 2017

OSUR Guru Trades in Q1 2017

Ken Fisher 503,594 sh (+48.57%)
» More
» Details

Insider Trades

Latest Guru Trades with OSUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:IRTC, NAS:LMNX, OTCPK:NNCSF, NAS:ATRC, NAS:ELGX, NAS:ATRI, NAS:ANGO, NAS:LMAT, NAS:NVCR, NAS:MLAB, NAS:ATRS, OTCPK:AMSJF, OTCPK:GMDTF, AMEX:CRHM, NAS:STAA, NAS:PLSE, NAS:ENTL, NAS:CFMS, NAS:UTMD, NAS:DSCI » details
Traded in other countries:EP3.Germany,
Headquarter Location:USA
OraSure Technologies Inc develops, manufactures, markets and sells oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies.

OraSure Technologies Inc was formed in May 5, 2000 under Delaware law solely for the purposes of combining two companies, STC Technologies, Inc. and Epitope, Inc. and changing the state of incorporation of Epitope from Oregon to Delaware. The Company is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests that are performed at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. One of its diagnostic products, the OraQuick In-Home HIV Test got approved by the U.S. FDA for sale in the over-the-counter or consumer retail markets in the United States. Its in vitro diagnostic testing is the process of analyzing oral fluid, blood, urine and other bodily fluids or tissue for the presence of specific substances or markers. Through its subsidiary, DNAG, the Company manufacture and sell kits that are used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetics, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. The Company owns rights to trademarks and service marks that are necessary to conduct its business as currently operated. In the United States, it owns the OraSure, Intercept, OraQuick, OraQuick ADVANCE, Histofreezer, OraSure QuickFlu, Q.E.D., Oragene, ORAcollect, OMNIgene, Performagene, PrepIT, HEMAgene, and AUTO-LYTE. The competitors include medical diagnostic companies and specialized biotechnology firms, as well as pharmaceutical companies with biotechnology divisions The Company is subject to other federal and state laws targeting fraud and abuse in the healthcare industry, including false claims laws, marketing conduct laws and laws constraining the sales, marketing and other promotional activities of manufacturers of medical devices by limiting the kinds of financial arrangements, including sales programs, with physicians, hospitals, laboratories and other potential purchasers of medical devices.

Top Ranked Articles about OraSure Technologies Inc

OraSure Technologies Earnings Conference Call Invitation

Ratios

vs
industry
vs
history
PE Ratio 38.56
OSUR's PE Ratio is ranked lower than
63% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. OSUR: 38.56 )
Ranked among companies with meaningful PE Ratio only.
OSUR' s PE Ratio Range Over the Past 10 Years
Min: 10.93  Med: 68.51 Max: 500.83
Current: 38.56
10.93
500.83
Forward PE Ratio 34.48
OSUR's Forward PE Ratio is ranked lower than
78% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. OSUR: 34.48 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 38.56
OSUR's PE Ratio without NRI is ranked lower than
62% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. OSUR: 38.56 )
Ranked among companies with meaningful PE Ratio without NRI only.
OSUR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.96  Med: 68.5 Max: 500.83
Current: 38.56
10.96
500.83
Price-to-Owner-Earnings 51.61
OSUR's Price-to-Owner-Earnings is ranked lower than
78% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. OSUR: 51.61 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
OSUR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.6  Med: 50.38 Max: 5235
Current: 51.61
12.6
5235
PB Ratio 3.93
OSUR's PB Ratio is ranked lower than
55% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. OSUR: 3.93 )
Ranked among companies with meaningful PB Ratio only.
OSUR' s PB Ratio Range Over the Past 10 Years
Min: 0.94  Med: 2.44 Max: 6.45
Current: 3.93
0.94
6.45
PS Ratio 5.76
OSUR's PS Ratio is ranked lower than
71% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. OSUR: 5.76 )
Ranked among companies with meaningful PS Ratio only.
OSUR' s PS Ratio Range Over the Past 10 Years
Min: 1.54  Med: 3.8 Max: 7.04
Current: 5.76
1.54
7.04
Price-to-Free-Cash-Flow 40.21
OSUR's Price-to-Free-Cash-Flow is ranked lower than
67% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. OSUR: 40.21 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
OSUR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.44  Med: 71.52 Max: 418.8
Current: 40.21
11.44
418.8
Price-to-Operating-Cash-Flow 32.45
OSUR's Price-to-Operating-Cash-Flow is ranked lower than
76% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. OSUR: 32.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OSUR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.73  Med: 32.31 Max: 2795
Current: 32.45
9.73
2795
EV-to-EBIT 31.91
OSUR's EV-to-EBIT is ranked lower than
66% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. OSUR: 31.91 )
Ranked among companies with meaningful EV-to-EBIT only.
OSUR' s EV-to-EBIT Range Over the Past 10 Years
Min: -760.8  Med: -7 Max: 630
Current: 31.91
-760.8
630
EV-to-EBITDA 24.91
OSUR's EV-to-EBITDA is ranked lower than
73% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. OSUR: 24.91 )
Ranked among companies with meaningful EV-to-EBITDA only.
OSUR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1516.5  Med: -6.9 Max: 326.4
Current: 24.91
-1516.5
326.4
Current Ratio 9.02
OSUR's Current Ratio is ranked higher than
94% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. OSUR: 9.02 )
Ranked among companies with meaningful Current Ratio only.
OSUR' s Current Ratio Range Over the Past 10 Years
Min: 2.4  Med: 6.81 Max: 14.78
Current: 9.02
2.4
14.78
Quick Ratio 8.34
OSUR's Quick Ratio is ranked higher than
95% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. OSUR: 8.34 )
Ranked among companies with meaningful Quick Ratio only.
OSUR' s Quick Ratio Range Over the Past 10 Years
Min: 1.97  Med: 6.19 Max: 14.11
Current: 8.34
1.97
14.11
Days Inventory 110.49
OSUR's Days Inventory is ranked higher than
59% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. OSUR: 110.49 )
Ranked among companies with meaningful Days Inventory only.
OSUR' s Days Inventory Range Over the Past 10 Years
Min: 84.17  Med: 116.55 Max: 134.26
Current: 110.49
84.17
134.26
Days Sales Outstanding 56.45
OSUR's Days Sales Outstanding is ranked higher than
58% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. OSUR: 56.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
OSUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.8  Med: 59.07 Max: 76.49
Current: 56.45
47.8
76.49
Days Payable 42.10
OSUR's Days Payable is ranked lower than
60% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. OSUR: 42.10 )
Ranked among companies with meaningful Days Payable only.
OSUR' s Days Payable Range Over the Past 10 Years
Min: 38.26  Med: 45.41 Max: 65.49
Current: 42.1
38.26
65.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.10
OSUR's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. OSUR: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OSUR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -40.2  Med: -6.3 Max: 11
Current: -0.1
-40.2
11

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.54
OSUR's Price-to-Net-Cash is ranked higher than
77% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.17 vs. OSUR: 7.54 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OSUR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.88  Med: 6.5 Max: 101.25
Current: 7.54
2.88
101.25
Price-to-Net-Current-Asset-Value 5.44
OSUR's Price-to-Net-Current-Asset-Value is ranked higher than
63% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. OSUR: 5.44 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OSUR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.04  Med: 7.81 Max: 55
Current: 5.44
2.04
55
Price-to-Tangible-Book 4.66
OSUR's Price-to-Tangible-Book is ranked higher than
52% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. OSUR: 4.66 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OSUR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.62  Med: 6.61 Max: 29.57
Current: 4.66
1.62
29.57
Price-to-Intrinsic-Value-Projected-FCF 3.79
OSUR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
77% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. OSUR: 3.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OSUR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.59  Med: 3.39 Max: 15.31
Current: 3.79
1.59
15.31
Price-to-Median-PS-Value 1.52
OSUR's Price-to-Median-PS-Value is ranked lower than
70% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. OSUR: 1.52 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OSUR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.54 Max: 17.37
Current: 1.52
0.64
17.37
Price-to-Graham-Number 2.78
OSUR's Price-to-Graham-Number is ranked lower than
53% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. OSUR: 2.78 )
Ranked among companies with meaningful Price-to-Graham-Number only.
OSUR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.52  Med: 2.8 Max: 8.59
Current: 2.78
1.52
8.59
Earnings Yield (Greenblatt) % 3.13
OSUR's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. OSUR: 3.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OSUR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 3.1 Max: 6.1
Current: 3.13
0.2
6.1
Forward Rate of Return (Yacktman) % 47.51
OSUR's Forward Rate of Return (Yacktman) % is ranked higher than
96% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. OSUR: 47.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
OSUR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -84.8  Med: 0.35 Max: 60.4
Current: 47.51
-84.8
60.4

More Statistics

Revenue (TTM) (Mil) $128.2
EPS (TTM) $ 0.34
Beta1.46
Short Percentage of Float6.34%
52-Week Range $5.57 - 13.30
Shares Outstanding (Mil)58.41

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 135 136
EPS ($) 0.38 0.24
EPS without NRI ($) 0.38 0.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OSUR

Headlines

Articles On GuruFocus.com
OraSure Technologies Earnings Conference Call Invitation Apr 12 2017 
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 
Weekly CFO Sells Highlight: OSUR, DKS, P, MGAM, EROC Jul 09 2012 
Weekly CFO Sells Highlight: OSUR, BMC, EF, HAIN, GCI, VRSK, FIO May 21 2012 
Weekly CFO Sells Highlight: KKD, OSUR, LVLT, OVTI Jul 11 2011 
OraSure Technologies Inc. Reports Operating Results (10-Q) Nov 09 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) May 06 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) Nov 05 2009 
OraSure Technologies Inc. Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
Abbott Laboratories Agrees to Acquire Alere at Lower Price Apr 17 2017
OraSure Technologies Earnings Conference Call Invitation Apr 12 2017
Zimmer Biomet (ZBH) Upgraded to Hold on Solid Prospects Apr 10 2017
Medtronic Initiates Product Recall, A Drag on Neurosurgery Apr 10 2017
VWR Corp Continues its Acquisition Spree with MESM Buyout Apr 10 2017
Medtronic (MDT) Less-Invasive HVAD Pump Results Positive Apr 07 2017
Medtronic HVAD System Results Positive for Long-Term Therapy Apr 06 2017
IDEXX Laboratories' CAG Revenues Solid, Competition Rife Apr 06 2017
Walgreens, Prime Form Central Specialty & Mail Service Company Apr 04 2017
NuVasive Receives FDA 510(k) Clearance in Cervical Spine Apr 03 2017
Boston Scientific (BSX) Inks Agreement to Acquire Symetis SA Mar 31 2017
Genomic Health's GPS Predicts Metastatic Prostate Cancer Mar 30 2017
NuVasive (NUVA) Gets FDA 510(k) Clearance for CoRoent System Mar 30 2017
QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics Mar 30 2017
Integra LifeSciences Expands Cadence System Commercially Mar 29 2017
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo Mar 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)